View ValuationVerici Dx 将来の成長Future 基準チェック /06現在、 Verici Dxの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • Apr 08Verici Dx plc Provides Earnings Guidance for the Year 2024Verici Dx plc provided earnings guidance for the year 2024. For the year, the company expected to report full year revenues of $3.3 million.すべての更新を表示Recent updatesお知らせ • May 20Verici Dx plc Announces Publication Validating Pre-Transplant Gene Signature Test For Predicting Early Acute Rejection In Kidney Transplant RecipientsVerici Dx plc announced the publication of a peer-reviewed clinical validation study of the Pre-Transplant Rejection Assessment (PTRA) test that stratifies patients undergoing deceased donor kidney transplantation as to their risk of acute rejection in the first two months post-transplant. The study, entitled “A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assay to Predict Early Acute Rejection” was published in Kidney360. The PTRA test is commercially marketed by Thermo Fisher Scientific. The test consists of an RNA signature comprised of 29 genes involved in oxidative stress, endothelial injury, metabolic regulation, as well as immune pathways associated with T cell– and antibody-mediated mechanisms of rejection. The test was observed in the clinical validation study to operate mostly independently of donor characteristics, focusing instead on an intrinsic, recipient-specific rejection phenotype, and demonstrates superior performance compared with standard risk features. PTRA outperformed conventional risk assessment tools, including panel reactive antibodies (PRA) in the ability to predict EAR in the first two months following transplant. Currently, kidney transplant recipients receive standardized immunosuppressive regimens, with more aggressive therapy often reserved for patients perceived as high-risk, typically based on broad criteria such as high PRA levels. However, these conventional risk features have limited predictive value, which can lead to unnecessary over-suppression and risks related to toxicity, infections and malignancy. Despite decades of progress in transplant medicine, clinicians still rely largely on broad, population-based risk markers that lack the precision needed to guide more individualized care. As a result, immunosuppressive strategies have remained largely one-size-fits-all for more than a decade. The Pre-Transplant Rejection Assessment (PTRA) test is a laboratory developed test that is used for clinical purposes by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA) or CE marked in the EU as an in vitro diagnostic test.お知らせ • Apr 18Verici Dx plc Appoints Keith Gilliard as Senior Director of SalesVerici Dx plc announced that Keith Gilliard was also appointed as Senior Director of Sales to lead the sales team, in a non-Board position. Keith has previously held senior sales roles at Waters Medical Systems, OrganOx Inc., CareDx Inc., Bristol-Myers Squibb and Novartis Pharmaceuticals.お知らせ • Oct 08Verici Dx plc Announces Board Changes, Effective October 6, 2025Verici Dx plc announced the appointment to the Board of Aubrey Powell, as Non-executive Director, with immediate effect. At the same time, Dr Erik Lium, Non-executive Director since August 2020 and representative of Mount Sinai on the Board, will step down from the Board with immediate effect. Aubrey has over 30 years' experience in supporting and advising growth companies, 26 of which have been spent in investment banking and corporate finance. He trained at Salomon Brothers (now Citi) for two years before transitioning to small and mid-cap roles at Panmure Gordon where he spent 12 years (including buyside investment and portfolio company support, as well as early-stage public companies at Durlacher prior to Panmure Gordon's reverse takeover in April 2005). Aubrey worked at N+1 Singer, which became Singer Capital Markets, from early 2012 to mid-2024, serving as an AIM Qualified Executive and advising Main Market companies, as Sponsor, on their obligations. Aubrey has extensive experience in deal execution in equity capital markets and M&A, for public companies as well as private, and has focused predominantly on Healthcare and Life Sciences, TMT and other technology-enabled businesses, over the course of his career. He brings a blend of skills from corporate finance to deal-making, as well as a strong track record of effectively guiding clients through reporting cycles, which supports his proposed role as a member of the Audit Committee, as well as advising on their wider regulatory and investor obligations including corporate governance. Previous experience also includes strategic consultancy covering growth and investment decision-making, as well as corporate communications, and working in biotech research for ICI Pharmaceuticals. In accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules, Aubrey Richard Powell (aged 54) currently holds the following directorship: Aubrey Powell Consulting (APC) Limited. Previous directorships or partnerships of which the director has been a director or partner over the last five years: Apus Sequestration LLP and Maia Green LLP. Mr. Powell holds no shares in the Company.お知らせ • Jul 29Verici Dx plc has completed a Follow-on Equity Offering in the amount of £0.431434 million.Verici Dx plc has completed a Follow-on Equity Offering in the amount of £0.431434 million. Security Name: Ordinary shares Security Type: Common Stock Securities Offered: 86,286,792 Price\Range: £0.005お知らせ • Jul 22+ 1 more updateVerici Dx plc has filed a Follow-on Equity Offering in the amount of £0.5 million.Verici Dx plc has filed a Follow-on Equity Offering in the amount of £0.5 million. Security Name: Ordinary shares Security Type: Common Stock Securities Offered: 100,000,000 Price\Range: £0.005お知らせ • Jul 21Verici Dx plc has filed a Follow-on Equity Offering in the amount of £5.037195 million.Verici Dx plc has filed a Follow-on Equity Offering in the amount of £5.037195 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,000,000,000 Price\Range: £0.005 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,439,092 Price\Range: £0.005 Transaction Features: Regulation S; Subsequent Direct Listingお知らせ • Jun 30Verici Dx plc, Annual General Meeting, Jul 29, 2025Verici Dx plc, Annual General Meeting, Jul 29, 2025. Location: shoosmiths llp, no 1 bow churchyard, ec4m 9dq, london United Kingdomお知らせ • Apr 08Verici Dx plc Provides Earnings Guidance for the Year 2024Verici Dx plc provided earnings guidance for the year 2024. For the year, the company expected to report full year revenues of $3.3 million.お知らせ • Jul 12Verici Dx plc to Report Q2, 2024 Results on Jul 15, 2024Verici Dx plc announced that they will report Q2, 2024 results on Jul 15, 2024お知らせ • Jun 08Verici Dx plc, Annual General Meeting, Jun 25, 2024Verici Dx plc, Annual General Meeting, Jun 25, 2024. Location: shoosmiths llp, no 1 bow churchyard, ec4m 9dq, london United Kingdomお知らせ • May 31+ 1 more updateVerici Dx plc to Report Fiscal Year 2023 Results on May 30, 2024Verici Dx plc announced that they will report fiscal year 2023 results on May 30, 2024お知らせ • Feb 14Verici Dx plc has completed a Follow-on Equity Offering in the amount of £6.5 million.Verici Dx plc has completed a Follow-on Equity Offering in the amount of £6.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 69,111,111 Price\Range: £0.09 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,111,111 Price\Range: £0.09 Transaction Features: Regulation S; Subsequent Direct Listingお知らせ • Jan 25+ 1 more updateVerici Dx plc has filed a Follow-on Equity Offering in the amount of £6.5 million.Verici Dx plc has filed a Follow-on Equity Offering in the amount of £6.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 69,111,111 Price\Range: £0.09 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,111,111 Price\Range: £0.09 Transaction Features: Regulation S; Subsequent Direct Listingお知らせ • Jan 24Verici Dx plc, Annual General Meeting, Feb 19, 2024Verici Dx plc, Annual General Meeting, Feb 19, 2024, at 12:00 Coordinated Universal Time. Location: the offices of Shoosmiths London at No. 1 Bow Churchyard London United Kingdom Agenda: To approve the total number of new Ordinary Shares to be issued pursuant to the Fundraising and Admission.お知らせ • Jan 08Verici Dx plc Announces Medicare National Payment Rate for Tutiviatm and Claravatm Effective as of January 1, 2024Verici Dx plc announced that the Centers for Medicare & Medicaid Services released the Clinical Laboratory Fee Schedule payment rate of $2,650 established through the "gapfill" process for both Tutiviatm (CPT 0320U), its post-transplant test focused upon acute cellular rejection, and Claravatm (CPT 0319U), its pre-transplant prognosis test for the risk of early acute rejection. This rate is effective as of January 1, 2024. Having a national payment rate established by CMS represents a step toward securing reimbursement for testing by Medicare, a national health insurance program in the US that covers 63.9 million patients. Gapfill pricing is a method used by CMS to establish a payment rate for clinical diagnostic laboratory tests when no comparable test is priced on the CLFS and involves setting the payment rate for the test at the median of rates established by local Medicare contractors.お知らせ • Jul 22Verici Dx plc Announces CLIA Certificate of Compliance Update US Clinical Laboratory Now Fully Accredited in 49 StatesVerici Dx plc announced that further to the RNS dated 2 March 2023, the Company has received compliance authorisation for the operation of its commercial clinical laboratory testing in respect of samples from an additional four US states, including the important addition of California, with the Company laboratory now fully accredited in a total of 49 states. Together with the CLIA certification previously obtained from the Centers for Medicare & Medicaid ("CMS"), clinicians at transplant medical centres in these additional states are now enabled to order Verici Dx's transplant tests, expanding the Company's commercial reach. California has consistently accounted for over 10% of the national US volume of kidney transplant procedures in each year since 1998 and has conducted the highest volume of transplants by any state each year over the same period. Verici Dx launched its first product, Tutivia™, for the detection of acute rejection in kidney post-transplant patients, in January 2023 and recently announced the successful validation of Clarava™, a first-in-class pre-transplant prognosis test for the risk of early acute rejection in deceased donor recipients, which it expects to launch later this year. The additional state accreditations provide further validation of Verici Dx's clinical laboratory for its tests to be used by transplant clinicians across the US. The Company continues to work towards full accreditation in the final state of New York, which has its own compliance requirements. The CLIA certification and additional state approvals further exemplify Verici's commitment to a quality-focused approach to providing advanced kidney transplant diagnostic services to clinicians and patients in need.お知らせ • Jul 04Verici Dx plc Announces Successful Validation Results from Its Prospective, Blinded, International Multi-Centre Clinical Validation Study for ClaravaVerici Dx plc announced successful validation results from its prospective, blinded, international multi-centre clinical validation study for Clarava™?. Clarava™?, is the first pre-transplant prognostic test to enable measurement of a patient's immune response to assess the risk of early kidney graft rejection. The validation study represents a significant demonstration of Clarava™? as a predictive test capable of informing a clear, actionable response from clinicians for an estimated 65,000 eligible patients on an annual basis. Verici Dx is on track to commence the initial US commercial launch of Clarava™? before the end of 2023. The Company has received a preliminary Medicare gapfill median rate of $2,650 for Clarava™? from the Centers for Medicare & Medicaid Services. The Clarava™ study, which included a broad and diverse group of 122 patients preparing to receive a kidney transplant and a range of rejection outcomes across 13 centres, demonstrated a statistically significant result with a sensitivity of 78% and specificity of 64%, identifying patients that are at increased risk for a kidney rejection event in the critical first 60 to 90 days post-transplant, after receiving a kidney from a deceased donor ("DD"). Study data analysis of the clinical performance of Clarava™ demonstrated differentiation of high-risk and low-risk patient groups, determining that patients of high risk were approximately six times more likely to have a rejection than those of low risk. This represents a significant demonstration of Clarava™ as a predictive test capable of informing for a clear, actionable response from clinicians. Whilst DDs provide the majority of kidney transplants, the Company will be also exploring further samples drawn from Living Donor (LD) transplant recipients, in addition to assessing the anticipated combination of using our pre-transplant test, Clarava™ in conjunction with our post-transplant test, Tutivia™. Clarava™ is the only pre-transplant test of its kind that can risk stratify patients based on their likely immune response to a transplanted organ. This allows clinicians to identify patients most likely to require increased monitoring, including adjustments in the type, dose, and duration of immunosuppressive agents. Existing approaches to assess rejection risk are standardized and typically based on the recipient's race, age, previous transplant history and whether they have antibodies against common donor antigens. As reported, the Clarava™ personalized risk assessment is especially important for the expanding DD transplant population.お知らせ • Jun 06Verici Dx plc, Annual General Meeting, Jun 29, 2023Verici Dx plc, Annual General Meeting, Jun 29, 2023, at 13:00 Coordinated Universal Time. Location: Avon House, 19 Stanwell Road, Penarth, Cardiff Wales United Kingdomお知らせ • May 31Verici Dx plc to Report Fiscal Year 2022 Results on Jun 05, 2023Verici Dx plc announced that they will report fiscal year 2022 results on Jun 05, 2023 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Verici Dx は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:VRCD.F - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20254N/A-9N/A16/30/20252-8-7-6N/A3/31/20253-7-6-6N/A12/31/20243-6-6-6N/A9/30/20244-5-6-6N/A6/30/20244-5-6-6N/A3/31/20243-7-7-6N/A12/31/20231-9-7-7N/A9/30/20231-10-9-8N/A6/30/20230-11-10-10N/A3/31/20230-11-11-10N/A12/31/2022N/A-11-11-10N/A9/30/2022N/A-11-10-9N/A6/30/2022N/A-11-10-9N/A3/31/2022N/A-10-8-7N/A12/31/2021N/A-8-7-6N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: VRCD.Fの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: VRCD.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: VRCD.Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: VRCD.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: VRCD.Fの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: VRCD.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/05 19:06終値2026/03/12 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Verici Dx plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 08Verici Dx plc Provides Earnings Guidance for the Year 2024Verici Dx plc provided earnings guidance for the year 2024. For the year, the company expected to report full year revenues of $3.3 million.
お知らせ • May 20Verici Dx plc Announces Publication Validating Pre-Transplant Gene Signature Test For Predicting Early Acute Rejection In Kidney Transplant RecipientsVerici Dx plc announced the publication of a peer-reviewed clinical validation study of the Pre-Transplant Rejection Assessment (PTRA) test that stratifies patients undergoing deceased donor kidney transplantation as to their risk of acute rejection in the first two months post-transplant. The study, entitled “A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assay to Predict Early Acute Rejection” was published in Kidney360. The PTRA test is commercially marketed by Thermo Fisher Scientific. The test consists of an RNA signature comprised of 29 genes involved in oxidative stress, endothelial injury, metabolic regulation, as well as immune pathways associated with T cell– and antibody-mediated mechanisms of rejection. The test was observed in the clinical validation study to operate mostly independently of donor characteristics, focusing instead on an intrinsic, recipient-specific rejection phenotype, and demonstrates superior performance compared with standard risk features. PTRA outperformed conventional risk assessment tools, including panel reactive antibodies (PRA) in the ability to predict EAR in the first two months following transplant. Currently, kidney transplant recipients receive standardized immunosuppressive regimens, with more aggressive therapy often reserved for patients perceived as high-risk, typically based on broad criteria such as high PRA levels. However, these conventional risk features have limited predictive value, which can lead to unnecessary over-suppression and risks related to toxicity, infections and malignancy. Despite decades of progress in transplant medicine, clinicians still rely largely on broad, population-based risk markers that lack the precision needed to guide more individualized care. As a result, immunosuppressive strategies have remained largely one-size-fits-all for more than a decade. The Pre-Transplant Rejection Assessment (PTRA) test is a laboratory developed test that is used for clinical purposes by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA) or CE marked in the EU as an in vitro diagnostic test.
お知らせ • Apr 18Verici Dx plc Appoints Keith Gilliard as Senior Director of SalesVerici Dx plc announced that Keith Gilliard was also appointed as Senior Director of Sales to lead the sales team, in a non-Board position. Keith has previously held senior sales roles at Waters Medical Systems, OrganOx Inc., CareDx Inc., Bristol-Myers Squibb and Novartis Pharmaceuticals.
お知らせ • Oct 08Verici Dx plc Announces Board Changes, Effective October 6, 2025Verici Dx plc announced the appointment to the Board of Aubrey Powell, as Non-executive Director, with immediate effect. At the same time, Dr Erik Lium, Non-executive Director since August 2020 and representative of Mount Sinai on the Board, will step down from the Board with immediate effect. Aubrey has over 30 years' experience in supporting and advising growth companies, 26 of which have been spent in investment banking and corporate finance. He trained at Salomon Brothers (now Citi) for two years before transitioning to small and mid-cap roles at Panmure Gordon where he spent 12 years (including buyside investment and portfolio company support, as well as early-stage public companies at Durlacher prior to Panmure Gordon's reverse takeover in April 2005). Aubrey worked at N+1 Singer, which became Singer Capital Markets, from early 2012 to mid-2024, serving as an AIM Qualified Executive and advising Main Market companies, as Sponsor, on their obligations. Aubrey has extensive experience in deal execution in equity capital markets and M&A, for public companies as well as private, and has focused predominantly on Healthcare and Life Sciences, TMT and other technology-enabled businesses, over the course of his career. He brings a blend of skills from corporate finance to deal-making, as well as a strong track record of effectively guiding clients through reporting cycles, which supports his proposed role as a member of the Audit Committee, as well as advising on their wider regulatory and investor obligations including corporate governance. Previous experience also includes strategic consultancy covering growth and investment decision-making, as well as corporate communications, and working in biotech research for ICI Pharmaceuticals. In accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules, Aubrey Richard Powell (aged 54) currently holds the following directorship: Aubrey Powell Consulting (APC) Limited. Previous directorships or partnerships of which the director has been a director or partner over the last five years: Apus Sequestration LLP and Maia Green LLP. Mr. Powell holds no shares in the Company.
お知らせ • Jul 29Verici Dx plc has completed a Follow-on Equity Offering in the amount of £0.431434 million.Verici Dx plc has completed a Follow-on Equity Offering in the amount of £0.431434 million. Security Name: Ordinary shares Security Type: Common Stock Securities Offered: 86,286,792 Price\Range: £0.005
お知らせ • Jul 22+ 1 more updateVerici Dx plc has filed a Follow-on Equity Offering in the amount of £0.5 million.Verici Dx plc has filed a Follow-on Equity Offering in the amount of £0.5 million. Security Name: Ordinary shares Security Type: Common Stock Securities Offered: 100,000,000 Price\Range: £0.005
お知らせ • Jul 21Verici Dx plc has filed a Follow-on Equity Offering in the amount of £5.037195 million.Verici Dx plc has filed a Follow-on Equity Offering in the amount of £5.037195 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,000,000,000 Price\Range: £0.005 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,439,092 Price\Range: £0.005 Transaction Features: Regulation S; Subsequent Direct Listing
お知らせ • Jun 30Verici Dx plc, Annual General Meeting, Jul 29, 2025Verici Dx plc, Annual General Meeting, Jul 29, 2025. Location: shoosmiths llp, no 1 bow churchyard, ec4m 9dq, london United Kingdom
お知らせ • Apr 08Verici Dx plc Provides Earnings Guidance for the Year 2024Verici Dx plc provided earnings guidance for the year 2024. For the year, the company expected to report full year revenues of $3.3 million.
お知らせ • Jul 12Verici Dx plc to Report Q2, 2024 Results on Jul 15, 2024Verici Dx plc announced that they will report Q2, 2024 results on Jul 15, 2024
お知らせ • Jun 08Verici Dx plc, Annual General Meeting, Jun 25, 2024Verici Dx plc, Annual General Meeting, Jun 25, 2024. Location: shoosmiths llp, no 1 bow churchyard, ec4m 9dq, london United Kingdom
お知らせ • May 31+ 1 more updateVerici Dx plc to Report Fiscal Year 2023 Results on May 30, 2024Verici Dx plc announced that they will report fiscal year 2023 results on May 30, 2024
お知らせ • Feb 14Verici Dx plc has completed a Follow-on Equity Offering in the amount of £6.5 million.Verici Dx plc has completed a Follow-on Equity Offering in the amount of £6.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 69,111,111 Price\Range: £0.09 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,111,111 Price\Range: £0.09 Transaction Features: Regulation S; Subsequent Direct Listing
お知らせ • Jan 25+ 1 more updateVerici Dx plc has filed a Follow-on Equity Offering in the amount of £6.5 million.Verici Dx plc has filed a Follow-on Equity Offering in the amount of £6.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 69,111,111 Price\Range: £0.09 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,111,111 Price\Range: £0.09 Transaction Features: Regulation S; Subsequent Direct Listing
お知らせ • Jan 24Verici Dx plc, Annual General Meeting, Feb 19, 2024Verici Dx plc, Annual General Meeting, Feb 19, 2024, at 12:00 Coordinated Universal Time. Location: the offices of Shoosmiths London at No. 1 Bow Churchyard London United Kingdom Agenda: To approve the total number of new Ordinary Shares to be issued pursuant to the Fundraising and Admission.
お知らせ • Jan 08Verici Dx plc Announces Medicare National Payment Rate for Tutiviatm and Claravatm Effective as of January 1, 2024Verici Dx plc announced that the Centers for Medicare & Medicaid Services released the Clinical Laboratory Fee Schedule payment rate of $2,650 established through the "gapfill" process for both Tutiviatm (CPT 0320U), its post-transplant test focused upon acute cellular rejection, and Claravatm (CPT 0319U), its pre-transplant prognosis test for the risk of early acute rejection. This rate is effective as of January 1, 2024. Having a national payment rate established by CMS represents a step toward securing reimbursement for testing by Medicare, a national health insurance program in the US that covers 63.9 million patients. Gapfill pricing is a method used by CMS to establish a payment rate for clinical diagnostic laboratory tests when no comparable test is priced on the CLFS and involves setting the payment rate for the test at the median of rates established by local Medicare contractors.
お知らせ • Jul 22Verici Dx plc Announces CLIA Certificate of Compliance Update US Clinical Laboratory Now Fully Accredited in 49 StatesVerici Dx plc announced that further to the RNS dated 2 March 2023, the Company has received compliance authorisation for the operation of its commercial clinical laboratory testing in respect of samples from an additional four US states, including the important addition of California, with the Company laboratory now fully accredited in a total of 49 states. Together with the CLIA certification previously obtained from the Centers for Medicare & Medicaid ("CMS"), clinicians at transplant medical centres in these additional states are now enabled to order Verici Dx's transplant tests, expanding the Company's commercial reach. California has consistently accounted for over 10% of the national US volume of kidney transplant procedures in each year since 1998 and has conducted the highest volume of transplants by any state each year over the same period. Verici Dx launched its first product, Tutivia™, for the detection of acute rejection in kidney post-transplant patients, in January 2023 and recently announced the successful validation of Clarava™, a first-in-class pre-transplant prognosis test for the risk of early acute rejection in deceased donor recipients, which it expects to launch later this year. The additional state accreditations provide further validation of Verici Dx's clinical laboratory for its tests to be used by transplant clinicians across the US. The Company continues to work towards full accreditation in the final state of New York, which has its own compliance requirements. The CLIA certification and additional state approvals further exemplify Verici's commitment to a quality-focused approach to providing advanced kidney transplant diagnostic services to clinicians and patients in need.
お知らせ • Jul 04Verici Dx plc Announces Successful Validation Results from Its Prospective, Blinded, International Multi-Centre Clinical Validation Study for ClaravaVerici Dx plc announced successful validation results from its prospective, blinded, international multi-centre clinical validation study for Clarava™?. Clarava™?, is the first pre-transplant prognostic test to enable measurement of a patient's immune response to assess the risk of early kidney graft rejection. The validation study represents a significant demonstration of Clarava™? as a predictive test capable of informing a clear, actionable response from clinicians for an estimated 65,000 eligible patients on an annual basis. Verici Dx is on track to commence the initial US commercial launch of Clarava™? before the end of 2023. The Company has received a preliminary Medicare gapfill median rate of $2,650 for Clarava™? from the Centers for Medicare & Medicaid Services. The Clarava™ study, which included a broad and diverse group of 122 patients preparing to receive a kidney transplant and a range of rejection outcomes across 13 centres, demonstrated a statistically significant result with a sensitivity of 78% and specificity of 64%, identifying patients that are at increased risk for a kidney rejection event in the critical first 60 to 90 days post-transplant, after receiving a kidney from a deceased donor ("DD"). Study data analysis of the clinical performance of Clarava™ demonstrated differentiation of high-risk and low-risk patient groups, determining that patients of high risk were approximately six times more likely to have a rejection than those of low risk. This represents a significant demonstration of Clarava™ as a predictive test capable of informing for a clear, actionable response from clinicians. Whilst DDs provide the majority of kidney transplants, the Company will be also exploring further samples drawn from Living Donor (LD) transplant recipients, in addition to assessing the anticipated combination of using our pre-transplant test, Clarava™ in conjunction with our post-transplant test, Tutivia™. Clarava™ is the only pre-transplant test of its kind that can risk stratify patients based on their likely immune response to a transplanted organ. This allows clinicians to identify patients most likely to require increased monitoring, including adjustments in the type, dose, and duration of immunosuppressive agents. Existing approaches to assess rejection risk are standardized and typically based on the recipient's race, age, previous transplant history and whether they have antibodies against common donor antigens. As reported, the Clarava™ personalized risk assessment is especially important for the expanding DD transplant population.
お知らせ • Jun 06Verici Dx plc, Annual General Meeting, Jun 29, 2023Verici Dx plc, Annual General Meeting, Jun 29, 2023, at 13:00 Coordinated Universal Time. Location: Avon House, 19 Stanwell Road, Penarth, Cardiff Wales United Kingdom
お知らせ • May 31Verici Dx plc to Report Fiscal Year 2022 Results on Jun 05, 2023Verici Dx plc announced that they will report fiscal year 2022 results on Jun 05, 2023